Showing results (31-40 of 145) with videos related to

Sort By:
Pageof 15
Cost Effectiveness and Resource Allocation : C/E|January 16, 2023
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainDolores Isla, Marta Lopez-Brea, María Espinosa, et al.
Lung Cancer (Amsterdam, Netherlands)|September 19, 2007
Early intervention with epoetin beta prevents severe anaemia in lung cancer patients receiving platinum-based chemotherapy: a subgroup analysis of the NeoPrevent studyJavier de Castro, Cristóbal Belda-Iniesta, Dolores Isla, et al.
Trends in Cancer|February 17, 2020
The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and ImmunotherapyAriel G Ramírez-Labrada, Dolores Isla, Angel Artal, et al.
Lung Cancer Management|April 8, 2020
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinibDolores Isla, Bartomeu Massuti, Martín Lázaro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 28, 2022
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel studyDolores Isla, Enriqueta Felip, Pilar Garrido, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 5, 2010
Dramatic complete response in patient with lung adenocarcinomaSara Serrano Solares, Dolores Isla Casado, María Jesús Vidal Losada, et al.
Cancers|July 24, 2019
Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer PatientsAlberto Rodrigo, Jorge L Ojeda, Sonia Vega, et al.
World Journal of Oncology|March 28, 2024
Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related ToxicityAlba Moratiel Pellitero, Maria Zapata Garcia, Marta Gascon Ruiz, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 25, 2017
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancerDolores Isla, Javier De Castro, Oscar Juan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2009
Lung cancer and treatment in elderly patients: the Achilles StudyMariano Provencio, Carlos Camps, Vicente Alberola, et al.
Pageof 15